Effect of diabetic duration on hemorheological properties and platelet aggregation in streptozotocin-induced diabetic rats

Eunseop Yeom, Hyeokjun Byeon & Sang Joon Lee

Diabetes mellitus with abnormal glucose concentration is associated with changes in hemorheological properties, endothelial function, and platelets hyperactivity. Disturbances may significantly be responsible for diabetes-related vascular complications. In this study, hemorheological and hemodynamic properties were measured according to diabetic duration after streptozotocin treatment in rats. For ex vivo measurements, an extracorporeal model was adopted. Flow rate and blood viscosity were measured using a microfluidic device. Erythrocyte aggregation and morphological parameters of erythrocytes were measured by modified erythrocyte sedimentation rate and the phase-contrast holography under in vitro conditions. The platelet aggregation and mean pressure in the femoral artery were estimated under ex vivo conditions. Hemorheological properties including blood viscosity, erythrocyte aggregation and shape parameters for the control group are significantly different with those for diabetic groups. The changes with respect to diabetic duration were relatively unnoticeable. However, the platelet aggregation is strongly dependent on the diabetic duration. Based on these results, hyperglycemia exposure may induce hemorheological variations in early stages of diabetes mellitus. High platelet aggregation may become more pronounced according to the diabetic duration caused by variations in hemorheological properties resulting in endothelial dysfunction. This study would be helpful in understanding the effects of diabetic duration on biophysical properties.

Diabetes mellitus is characterized by disordered metabolism and high hyperglycemia resulting from either low insulin level or high insulin resistance. Diabetes mellitus is associated with abnormal endothelial function, increase of arterial stiffness, platelet hyper-reactivity and hemorheological changes. These resultant disturbances may play a critical role in the etiology of diabetes-related vascular complications, including arteriosclerosis, cardiac autonomic neuropathy and myocardial infarction.

Among the variations, the viscosity increase of both plasma and whole blood caused by marked changes in hemorheological parameters, such as hematocrit, plasma proteins, erythrocyte aggregation, and deformability, can lead to the development of microvascular complications. Specifically, hemorheological changes contribute to the production of vasoactive materials, such as nitric oxide (NO), prostacyclin, and endothelin, by changing shear stress on the endothelial cells. The relationship between blood viscosity and peripheral vascular resistance was reported to be mediated by NO production.

In previous studies using diabetic models, it was demonstrated that hyperglycemia leads to hyperaggregation and low deformability of erythrocytes by changing hemoglobin and membrane proteins of erythrocyte, and serum proteins (fibrinogen and globulins). Such hemorheological changes are implicated in the progression of retinal failure in diabetic retinopathy and renal failure in diabetic nephropathy.

Endothelial dysfunction mainly results from imbalance between reduced bioavailability of NO and abundant formation of reactive oxygen species (ROS) in the vascular wall. This dysfunctional phenomenon is accelerated in diabetics. Impaired endothelial functions are observed in the very early stages of diabetes mellitus and
Blood viscosity and flow rate were repeatedly measured at intervals of 10 min for a total of 30 min after establishing the rat extracorporeal model. In this condition, response time, which is dependent on the flow rate, is less than 20 s. The time for observing the hydrodynamic balancing state is about 2 min. For minimization of dilution or blood loss due to ex vivo measurement, phosphate buffered saline (PBS; pH 7.4, Bio Solution, Korea) is only delivered at specific measurement instants. A blood sample was collected after 30 min of extracorporeal circulation to measure other biophysical properties including blood glucose, hematocrit, viscosity, the hydrodynamic balancing state was induced in the H-shaped microfluidic device by adjusting the injection flow rate of PBS solution, as depicted in the bottom insets of Fig. 1D.

To investigate between hemorheological properties and diabetes mellitus, various assessment techniques was adopted including rotational viscometer, ultrasonic diagnostic, erythrocyte sedimentation rate (ESR), filtration, 3D topography, optical tweezers, and microfluidic devices. However, rotational viscometer requires a large amount of blood samples for repetitive tests. Ultrasonic diagnostic needs calibration procedure with varying flow speed and hematocrits, due to dependency of these factors. The ESR results are influenced by the installation angle and surface condition of test tubes. Since most techniques used to measure erythrocyte deformability handle single cells, it is difficult to measure statistically-averaged biophysical properties for many cells. In addition, they usually measure hemorheological properties under in vitro conditions. External exposure of blood samples can modify the aggregability and deformability of erythrocytes.

For the measurement of biophysical properties under ex vivo condition, a rat extracorporeal loop model, circulating blood through an external loop that directly connects artery and vein, was employed in this study. A number of biophysical properties were measured with the lapse of time by inserting a microfluidic device into the rat extracorporeal model. Given that the risk of developing vascular complications related with diabetes mellitus is associated with the degree and duration of hyperglycemia, we examined the effects of duration of hyperglycemia on biophysical properties, including blood viscosity, flow rate, pressure, degree of erythrocyte aggregation, erythrocyte shape, and platelet adhesion using the rat extracorporeal model and other measurement techniques.

Table 1. Biophysical characteristics of normal and diabetic rat groups. Each value represents mean ± standard deviation. *p < 0.001: significant difference from the control group.

|                | Control          | DM (3 day)       | DM (7 day)       | DM (20 day)      |
|----------------|------------------|------------------|------------------|------------------|
| Weight (g)     | 404.2 ± 15.7     | 364.9 ± 24.0     | 319.3 ± 38.1     | 241.9 ± 20.4     |
| Blood sugar (mg/dL) | 67.7 ± 9.3      | 468.0 ± 49.2     | 455.0 ± 41.4     | 534.8 ± 39.4     |
| Hematocrit (%) | 0.52 ± 0.01      | 0.52 ± 0.03      | 0.52 ± 0.04      | 0.49 ± 0.02      |
| Fibrinogen (mg/mL)   | 3.2 ± 0.40      | 4.9 ± 0.25      | 5.10 ± 0.25      | 5.38 ± 0.30      |
| Platelets (×1000/µL) | 735 ± 33        | 689.6 ± 54      | 704 ± 57         | 644 ± 49         |

Results

Rat conditions. The toxic effect of streptozotocin (STZ) treatment destroys pancreatic beta cells and changes physiological conditions of rat model. Table 1 summarizes the biophysical characteristics for control and diabetic groups according to diabetic duration. The weight is gradually decreased in compliance with the duration of diabetes. Glucose concentration in blood samples was measured using an Accu-Chek® sensor instrument with test strips (Roche Diagnostics, Mannheim, Germany). Blood glucose for the control group is significantly lower than that for diabetic groups, but significant statistical difference is not observed among diabetic groups. Hematocrits are almost similar among all groups. The measured hematocrit values are relatively higher, compared with normal physiological condition. It may be related with the dehydration of the rat due to a long-operational time. The level of fibrinogen in the plasma was measured by fibrinogen ELISA kit (Abcam, Cambridge, MA) in accordance with the manufacturer’s instructions. Fibrinogen concentration for the diabetic groups is significantly higher than that for control group. The platelet counts were measured by a semiautomated haematology analyzer (Medonic CA 620). The platelet numbers for diabetic groups are slightly lower than that for control group.

Ex vivo blood viscosity. Blood viscosity and flow rate were repeatedly measured at intervals of 10 min for a total of 30 min after establishing the rat extracorporeal model. In this condition, response time, which is dependent on the flow rate, is less than 20 s. The time for observing the hydrodynamic balancing state is about 2 min. For minimization of dilution or blood loss due to ex vivo measurement, phosphate buffered saline (PBS; pH 7.4, Bio Solution, Korea) is only delivered at specific measurement instants. A blood sample was collected after 30 min of extracorporeal circulation to measure other biophysical properties including blood glucose, hematocrit, viscosity, the hydrodynamic balancing state was induced in the H-shaped microfluidic device by adjusting the injection flow rate of PBS solution, as depicted in the bottom insets of Fig. 1D.

Figure 1D shows the flow rate of PBS solution at the hydrodynamic balancing state and the flow rate of blood QBlood can be estimated at

$\mu_{Blood} = \frac{\rho \times \Delta P}{2 \times \eta \times W \times H}$

where $\rho$ is the density of blood, $\Delta P$ is the pressure gradient, $\eta$ is the viscosity of blood, and $W \times H$ is the cross-sectional area of the microchannel. To measure blood viscosity, the hydrodynamic balancing state was induced in the H-shaped microfluidic device by adjusting the injection flow rate of PBS solution, as depicted in the bottom insets of Fig. 1D.

Figure 1D shows the flow rate of PBS solution at the hydrodynamic balancing state (QPBS) and the flow rate of blood (QBlood) for the control rat sample. Although both flow rates QPBS and QBlood slightly increase and decrease for 30 min, its variances are not very noticeable. The variation of flow rate may be caused by some external factors including anesthetization and environmental stress. By using Eq. (3), blood viscosity $\mu_{Blood}$ can be estimated at specific measurement instants (Fig. 1E). Considering the slight variances of QPBS and QBlood, measured values of $\mu_{Blood}$ seem to be almost similar during the ex vivo measurements. The temporal variation of $\mu_{Blood}$ is inversely
correlated with that of $Q_{\text{PBS}}$ and $Q_{\text{Blood}}$, due to shear dependency of blood viscosity. Mean shear rate under ex vivo condition is approximately 2600 s$^{-1}$.

**Variation of in vitro blood viscosity.** Since the blood viscosity estimated under ex vivo condition depicts only the hemorheological property at a specific flow condition, the variation of blood viscosity according to shear rate was obtained by changing the flow rate of collected blood sample based on the relation between shear rate and flow rate. The input flow rate of a syringe pump was varied from 0.1 to 25 mL/h. Figure 2A shows variation of blood viscosity in a normal rat sample with respect to shear rate $\gamma$. A number of different fitting equations have been used to depict blood viscosity according to shear rate $\gamma$. Among these equations, the following Carreau model was adopted for blood viscosity prediction:

$$\mu = \mu_\infty + (\mu_0 - \mu_\infty) \left[1 + (\lambda \gamma)^n\right]^{-\frac{n-1}{2}}$$

where, $\mu_\infty$, $\mu_0$, $\lambda$, and $n$ represent viscosity values at infinite and zero shear rates, relaxation time, and power index, respectively. As expected, a line fitted with Carreau model is well matched with the measured viscosity data. A fitting parameter $\mu_0$ is depicted by the results in a box plot representation to compare different viscosity degree according to the duration of diabetes ($D_{\text{Diabetes}}$) (Fig. 2B). Mean value of $\mu_0$ for the control group is significantly lower than that for the diabetic groups. However, statistical difference between the diabetic groups is not observed.

**Variation of modified ESR.** To determine the extent of erythrocyte aggregation, the modified ESR value was measured. Aggregated erythrocytes are easily sedimented by gravity (Fig. 3A). Right panel of Fig. 3A shows optical images with respect to time. As expected, the volume of the erythrocyte-depleted plasma ($\Delta V$) is gradually increased with lapse of time. Different degrees of erythrocyte aggregation between groups were compared by calculating $V_{\text{ESR}}$ (Fig. 3C). Similar to the results of blood glucose and viscosity, $V_{\text{ESR}}$ values for diabetic groups are
markedly higher than that for the control group regardless of diabetic duration. The hyperaggregation of erythrocytes in diabetic groups can be elucidated by using the depletion theory. Since the osmotic force caused by the different concentrations of long-chain macromolecules between surface of erythrocyte and the bulk plasma makes adjacent erythrocytes aggregate together, the increased fibrinogen in STZ rat model gives rise to a high $\langle V \rangle$.

Variation of erythrocyte shapes. The cytoplasmic viscosity of erythrocyte is highly dependent on hyperglycaemia. Variation in the membrane lipid-protein interactions may alter viscoelastic properties of erythrocyte membrane. These abnormalities in erythrocyte membrane contribute to the changes in morphological features of erythrocytes in diabetic groups. The deformability of individual erythrocytes is closely related to the morphological feature of erythrocytes\cite{11}. Specifically, the surface area-to-volume ratio of a biconcave disc significantly contributes to the degree of deformability\cite{25}. In order to estimate the deformability of erythrocytes for each group, 3D shape of erythrocytes was measured by the phase-contrast digital holography. Figure 4 compares 3D morphologies of normal and diabetic erythrocytes. Since the shape changes according to the duration of diabetes are not significant, 3D morphology of a diabetic sample at the 20 days diabetic duration is only represented. Diabetic erythrocytes have relatively higher cell thickness compared to that of normal erythrocytes. However, significant shape changes, such as loss of biconcave shape and echinocyte shape transformation\cite{26}, are not observed.

To more systematically investigate the morphological changes of erythrocytes, some morphological parameters, such as perimeter, 2D area, perimeter-to-2D area ratio, volume, 3D surface, and surface area-to-volume ratio, are summarized in Table 2. Perimeter, 2D area, volume, and 3D surface do not show noticeable changes in the consideration of their relatively high standard deviations. However, the perimeter-to-area ratio and surface area-to-volume ratio for the control group are significantly different with those for diabetic groups. Similar to other hemorheological properties, changes in morphological properties between diabetic groups are relatively weak with no statistical difference.

Figure 2. Variation of blood viscosity measured under in vitro condition. (A) Variation of blood viscosity according to shear rate. A curve fitted with Carreau model is included. (B) Viscosity values at zero shear rate ($\mu_0$) in the Carreau model are depicted according to duration of diabetes ($D_{\text{diabetes}}$). The line in the box represents median value. ($^*p < 0.001$: significant difference from the control group).

Figure 3. Measured modified ESR values. (A) Schematic of the modified ESR measurement. After loading a blood sample in a disposable syringe (1 mL), the syringe is vertically disposed in the inverted position. Typical images show the sedimentation of erythrocytes in the blood sample with respect to time ($t$). The syringe was illustrated by the authors using SolidWorks software. (B) Variation of ESR value ($V_{\text{ESR}}$) according to $D_{\text{diabetes}}$. ($^*p < 0.001$: significant difference from the control group).
Discussion

Considering that glucose is an essential nutrient for body cells, abnormal glucose concentration may have a direct influence on the constituents and biochemical properties of blood circulating in vascular networks. In previous studies, it was found that STZ-induced diabetes mellitus significantly alter lipid composition, mRNA and plasma protein levels. Specifically, increase in soluble thrombomodulin (sTM), vWF and fibrinogen and plasma protein levels. Specifically, increase in soluble thrombomodulin (sTM), vWF and fibrinogen and plasma protein levels.

Figure 4. 3D morphology of erythrocytes. A modified version of common-path diffraction phase microscopy was utilized to measure 3D morphology of individual erythrocytes. Overall magnification is approximately 120 × . Blood sample was diluted in PBS solution with volume ratio of 1:200. Topography of (A) a control and (B) a diabetic erythrocyte after 20 days from STZ treatment. Color bar indicates the depth of the erythrocyte.

|                      | Control | DM (3 days) | DM (7 days) | DM (20 days) |
|----------------------|---------|-------------|-------------|--------------|
| Perimeter (μm)       | 20.96 ± 1.1 | 20.42 ± 0.76 | 21.33 ± 0.81 | 20.73 ± 0.75 |
| 2D area (μm²)        | 44.01 ± 2.4 | 41.14 ± 3.25 | 44.53 ± 2.07 | 42.38 ± 2.59 |
| Perimeter/Area (μm⁻¹)| 0.48 ± 0.02 | 0.50 ± 0.02 | 0.49 ± 0.02 | 0.49 ± 0.01 |
| Volume (fL)          | 81.71 ± 12.59 | 88.88 ± 10.94 | 88.57 ± 8.26 | 87.03 ± 9.89 |
| 3D surface area (μm³) | 111.20 ± 12.34 | 107.08 ± 9.07 | 111.32 ± 8.18 | 111.20 ± 5.91 |
| Surface area/volume (μm⁻¹) | 1.37 ± 0.10 | 1.22 ± 0.16 | 1.26 ± 0.12 | 1.29 ± 0.15 |

Table 2. Morphological parameters of erythrocyte between normal and diabetic groups. Each value represents mean ± standard deviation. *p < 0.1, **p < 0.05: significant difference from the control group.

Estimation of platelet aggregation under ex vivo condition. As depicted in Fig. 5A, the degree of platelet aggregation was estimated by quantifying the area of adhered platelets in the straight channel under ex vivo condition. Temporal variations of the area of adhered platelets were monitored to find the optimal condition in advance of the main experiments. Figure 5B shows extremely severe variation in Aplatelet for a diabetic rat model with the 30 days diabetic duration. Aplatelet slightly increases at the initial state after establishing the rat extracorporeal model. Subsequently, the adhered platelets are almost not observed until 20 min later. As depicted in insets (Fig. 5B(a–c)), some platelets are rapidly attached in the straight channel after 20 min. Given that large platelet aggregates are subjected to large force caused by increased fluidic resistance, large aggregates are suddenly detached from the microchannel at around t = 25 min. However, platelets are re-adhered and then the straight channel is completely blocked by platelet aggregates at 40 min. Based on this temporal variation of Aplatelet, the area of platelets Aplatelet at 30 min is used as the representative parameter to compare the platelet aggregation between the normal and diabetic groups.

Figure 5C shows a box plot representing Aplatelet at t = 30 min after the ex vivo measurement according to the duration of diabetes (Ddiabetes). Unlike other hemorheological properties such as blood viscosity, erythrocyte aggregation, and erythrocyte shape, the degree of platelet adhesion for diabetic groups is largely increased with diabetic duration Ddiabetes. As Ddiabetes increases, the standard deviation of Aplatelet also significantly increased. Platelet activated by hemodynamic features is primarily mediated by soluble fibrinogen and von Willebrand factor (vWF) which support both adhesion and aggregation of platelets. Thus, the enhanced fibrinogen and vWF in diabetic rat models induce hyper-adhesion of platelets (Table 1).

Observation of ex vivo hemodynamic conditions. Mean pressure variation was monitored during the ex vivo measurements. The different size of channels in the extracorporeal loop induces different shear rate at a certain part of the extracorporeal loop despite of the same flow rate. For reasonable estimation of mean pressure in the femoral artery (Partery), the viscosity value at a specific shear condition fitted by Eq (1) was applied to Eq (5).

Figure 6A shows temporal variation of Partery with the lapse of time under ex vivo condition for the control sample. Like flow rate results (Fig. 1D), Partery is slightly increased and then decreased in a 30 min period. A dotted line indicates the mean value of Partery during the experiment time. Partery was used as a parameter representing the hemodynamic condition for all groups. As depicted in the box plot of Fig. 6B, statistically different tendency of Partery is not observed for all groups.

Discussion

Considering that glucose is an essential nutrient for body cells, abnormal glucose concentration may have a direct influence on the constituents and biochemical properties of blood circulating in vascular networks. In previous studies, it was found that STZ-induced diabetes mellitus significantly alter lipid composition, mRNA and plasma protein levels. Specifically, increase in soluble thrombomodulin (sTM), vWF and fibrinogen and
decrease in activated factor XIII have also been reported in STZ diabetic models. These alterations can induce changes in hemorheological properties such as viscosity, hematocrit, plasma proteins, erythrocyte aggregation, and deformability, and platelet aggregation.

To investigate variation of hemorheological properties and platelet aggregation according diabetic duration, some measurement methods were adopted in the present study. Although *ex vivo* measurement can offer more reasonable data compared with *in vitro* measurement based on our previous studies, it is difficult to simultaneously measure various hemorheological properties under *ex vivo* conditions. Therefore, viscosity variation, erythrocyte aggregation, and shape were measured by *in vitro* experiments. Fortunately, platelet adhesion can be quantified without significant flow modification when blood flow is similar among *ex vivo* measurements. To check flow conditions of *ex vivo* measurements, pressures at the femoral artery were compared.

Among these hemorheological properties, blood viscosity has a profound impact on blood circulation. In this regard, the variation of viscosity according to shear rate was measured using the H-shaped microchannel. Diabetic rats were found to have relatively high viscosities compared to the control. These results are in agreement with previous studies and suggest a potential role of blood viscosity in diabetic complications.
Scientific Reports | 6:21913 | DOI: 10.1038/srep21913

fabrication of microfluidic devices.

Methods
Fabrication of microfluidic devices. A rectangular master replica mold (height = 80 \mu m) was fabricated using microelectromechanical system (MEMS) technologies based on soft lithography and deep reactive-ion etching. An H-shaped microfluidic device has two identical side channels with width (W) of 3000 \mu m and length of 14.4 mm. A bridge channel connecting both side channels has width of 100 \mu m and length of 2.4 mm. A straight microchannel has width (W2) of 1 mm and length of 10 mm. To initiate platelet aggregation in the straight microchannel, inlet region has narrow width about 100 \mu m and the microchannel was coated by collagen based on previous studies (Supplementary Fig. 1)40,45. After pouring Polydimethylsiloxane (PDMS; Sylgard 184, Dow
Preparation of extracorporeal model using diabetic rat samples. Male Sprague-Dawley rats were exposed to a 12/12 reverse-light cycle. Type 1 diabetes with hyperglycemia was induced by intraperitoneal injection of streptozotocin (STZ; 65 mg/kg in sterile saline) to rat samples under anesthesia with isoflurane and oxygen. Male Sprague-Dawley rats were exposed to a 12/12 reverse-light cycle. Type 1 diabetes with hyperglycemia was induced by intraperitoneal injection of streptozotocin (STZ; 65 mg/kg in sterile saline) to rat samples under anesthesia with isoflurane and oxygen. Rat samples were fasted for 24 h prior to the STZ injection, and then fasted for another 24 h. They were divided into four groups, depending on the duration of diabetes (control, 3, 7 and 20 days).

A rat extracorporeal model was adopted to measure some biophysical properties under ex vivo conditions (Fig. 1A)\(^{18}\). All experiments were conducted using 16-week-old rat samples, which were anesthetized with intramuscular injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). A PE-50 tube (ID = 0.58 mm, polyethylene tube) at one end of the extracorporeal loop was cannulated into the right jugular vein. Exact amount of heparin (1500 IU/mL/kg) was precisely injected into the right jugular vein for anticoagulation. After 10 min of heparin injection, another PE-50 tube at the other end of the loop was inserted into the left femoral artery. A pulsed-free microfluidic device with 1.5 mL air cavity was installed between the femoral artery and the inlet of the H-shaped microfluidic device to supply stabilized blood samples. The outlet of the H-shaped microchannel and the inlet of the straight microchannel were connected by a Tygon tube (ID = 250 μm). The blood passing through the extracorporeal conduits was returned to the jugular vein of the rat model. The cooling effect caused by the blood circulation through the extracorporeal loop was minimized by installing a heat chamber maintained at 36 °C to 37 °C. All experimental procedures were approved by the Animal Care and Ethics Committee of Pohang University of Science and Technology, and all methods were performed in accordance with the approved guidelines.

Micro-PIV technique for flow rate measurement. As shown in Fig. 1B, a micro-PIV was used to measure blood flows in the H-shaped microchannel. The microfluidic devices were mounted on the stage of an optical microscope (Nikon, Tokyo, Japan) with 4 × objective lens (NA = 0.1). Optical images of blood flows were consecutively acquired using a high-speed camera (FASTCAM SA 1.1, Photron Ltd., San Diego, USA) at a frame rate of 5000 fps. Before applying the cross-correlation PIV algorithm to each image pair, the captured images were cropped into images of 408 pixels × 320 pixels. The detailed procedures of micro-PIV technique employed in the present study were well described in our previous studies\(^{46,47}\). The size of each interrogation window was 16 pixels × 32 pixels with 50% overlapping. The obtained velocity fields were filtered using a 3 × 3 median kernel. Velocity profiles were obtained by averaging the velocity field along the flow direction (y-axis).

Based on our previous study\(^{15}\), the measured velocity information can be postulated to represent the mean velocity of erythrocytes in the whole depth, because the depth of correlation (δ_μ = 310 μm), which expresses the depth over which particles contribute to the cross-correlation analysis, is larger than the channel depth under present experiment condition. Therefore, the flow rate of blood (Q_{blood}) in the microchannel can be estimated using the following equation:

\[
Q_{\text{blood}} = \frac{W_1}{H} \int_0^H U(x) \, dx \times H
\]

where \(U(x)\) is the velocity profile at a specific lateral position \(x\); and \(W_1\) and \(H\) indicate the width and depth of the H-shaped microchannel, respectively.

Viscosity estimation. Blood sample and PBS solution were separately delivered into the two inlets of the H-shaped microfluidic device to estimate blood viscosity. The PBS solution was supplied using a syringe pump (neMESYS, Centoni GmbH, Germany) with a 5 mL plastic syringe (BD). When a blood sample does not move in the bridge channel (hydrodynamic balancing state), the viscosity of the blood sample (\(\mu_{\text{blood}}\)) can be simply estimated based on the following analytical formula:

\[
\mu_{\text{blood}} = \mu_{\text{PBS}} \frac{Q_{\text{PBS}}^B}{Q_{\text{blood}}}
\]

where, \(\mu_{\text{PBS}}\) and \(Q_{\text{PBS}}^B\) denote viscosity, and the flow rate of PBS solution at the hydrodynamic balancing condition, respectively. The viscosity of PBS solution (\(\mu_{\text{PBS}}\)) is approximately 1.00 ± 0.05 cP\(^{48}\). Details of viscosity estimation procedure were well described in our previous study\(^{46}\).

Modified erythrocyte sedimentation rate measurement. Modified ESR value was measured using a 1 mL plastic syringe (BD). Based on our previous results, the hematocrit of the blood samples was adjusted to 20% for effective measurement of erythrocyte aggregation using the modified ESR value\(^{15}\). After loading blood sample (0.9 mL) into a disposable syringe, the syringe was disposed in an inverted vertical posture (Fig. 3A). Snap shots of the syringe were continuously captured with a digital camera (D700, Nikon, Japan) at 5 min intervals for 12 h. Boundaries between erythrocytes and erythrocyte-depleted plasma were determined by adopting Canny's
method can be calculated by dividing the volume of erythrocyte-depleted plasma (ΔV) by the measurement time (t = 12 h).

Phase-contrast digital holography. Whole blood was diluted 1:200 in the PBS solution and then placed between slide glass and cover glass. Prepared blood sample was mounted on the stage of an upright microscope (Eclipse i50, Nikon) with 40 × objective lens (NA = 0.75). Additional relay optics were used to provide overall magnification of 120 ×. A modified version of common-path diffraction-related phase microscopy was utilized to measure the 3D morphological shape of erythrocytes. The laser beam (He–Ne laser; λ = 633 nm) is separated into two beams by a beam splitter. One beam passes through the test sample and the other beam, which is used as the reference beam, passes through a pinhole. A hologram, made by interference between the two beams, was captured by a charge-coupled device camera (PCO 2000, 2K × 2K pixel, 7.4 μm/pixel). An angular spectrum algorithm was employed for numerical reconstruction of hologram images. Perimeter, 2D projected area, 3D surface area and volume of erythrocytes were evaluated from the reconstructed phase images. The detailed procedures of hologram reconstruction and cell analysis were well described in our previous study.

Quantification of adhered platelets. Before establishing the rat extracorporeal model, the conduits, except for the straight microchannel, were incubated with 2% bovine serum albumin (Sigma, MO) for 1 h at room temperature to inhibit platelet deposition and fibrin adhesion. After 1 h, BSA is washed by PBS solution. A total of 60 images of blood flow and adhered platelets in the straight microchannel were consecutively acquired by the high-speed CMOS camera (FASTCAM SA 1.1) with time interval of 1 s at 30 min after establishing the extracorporeal rat model. In order to accurately distinguish the adhered platelets from the flowing blood, a correlation map, labeling the 2D correlation coefficient between small tiles of two consecutive images, was adopted (Fig. 5A). Each optical image was divided into small tiles of n × m. The 2D correlation coefficient (R) of tiles was calculated using the following equation:

\[
R(C_i, C_j) = \frac{\sum_{i,j}(A(i, j) - \overline{A})(B(i, j) - \overline{B})}{\sqrt{(\sum_{i,j}(A(i, j) - \overline{A})^2)(\sum_{i,j}(B(i, j) - \overline{B})^2)}}
\]

where A and B represent the tiles centered at (C_i, C_j) in two consecutive images, (i, j) is the pixel coordinate of the tile, and \( \overline{A} \) and \( \overline{B} \) denote the mean intensity of the tiles A and B, respectively. The size of each tile used in this study is 11 pixels × 11 pixels. The correlation maps were converted into binary images by applying the thresholding with an optimal value of Otsu’s algorithm. Finally, area for adhered platelets (A_platelet) is estimated by calculating the total number of any nonzero pixels in the binary image.

Estimation of mean pressure in the femoral artery. A discrete fluidic circuit of the present extracorporeal model is composed of fluidic resistances, air compliance of the pulse-free chamber, and flow rates. By adding pressure drops in the fluidic circuits from hydrodynamic balancing pressure in the microfluidic device, the mean pressure in the femoral artery (P_Artery) can be estimated using the following equation:

\[
P_{Artery} = \frac{128Q_{Blood}}{\pi} \left( \frac{\Delta L_1}{D_1^4} + \frac{\Delta L_2}{D_2^4} + \cdots + \frac{\Delta L_n}{D_n^4} \right) + P_{PBS}
\]

where, \( \mu_u, L_u \) and \( D_n \) represent the blood viscosity, characteristic length and hydraulics diameter at a certain part of the extracorporeal network (Supplementary Fig. 2). P_{PBS} denotes the hydrodynamic balancing pressure in the H-shaped microchannel. In the prediction of blood pressure, it is assumed that blood is circulated in the extracorporeal network without bleeding and no change in the fluidic resistance. Due to accumulation of platelet aggregates in the straight channel, the pressure in the artery (P_Artery) would be somewhat overestimated.

Statistical analysis. Results in each group indicate the mean value evaluated from five test samples. The statistical analysis of the data was carried out by Student t-test between control and diabetic groups. The statistical analysis among diabetic groups are not observed in all Tables and Figures.

References
1. Schafer, A. et al. Improved endothelial function and reduced platelet activation by chronic HMG-CoA-reductase inhibition with rosuvastatin in rats with streptozotocin-induced diabetes mellitus. Biochem. Pharmacol. 73, 1367–1375 (2007).
2. Wilkinson, I. B. et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM 93, 441–448 (2000).
3. Cho, Y. I., Mooney, M. P. & Cho, D. J. Hemorrhheological disorders in diabetes mellitus. J. Diabetes Sci. Technol. 2, 1130–1138 (2008).
4. Loomans, C. J. et al. Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53, 195–199 (2004).
5. Beckman, J. A., Creager, M. A. & Libby, P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 287, 2570–2581 (2002).
6. Tamariz, L. J. et al. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus. The atherosclerosis risk in communities (ARIC) study. Am. J. Epidemiol. 168, 1153–1160 (2008).
7. Ford, E. S. Leukocyte count, erythrocyte sedimentation rate, and diabetes incidence in a national sample of US adults. Am. J. Epidemiol. 155, 57–64 (2002).
8. Cloutier, G., Zimmer, A., Yu, F. T. & Chiasson, J. L. Increased shear rate resistance and fastest kinetics of erythrocyte aggregation in diabetes measured with ultrasound. Diabetes Care 31, 1400–1402 (2008).
9. Salazar-Vazquez, B. Y., Intaglietta, M., Rodriguez-Moran, M. & Guerrero-Romero, F. Blood pressure and hematocrit in diabetes and the role of endothelial responses in the variability of blood viscosity. Diabetes Care 29, 1523–1528 (2006).
10. Martini, J., Carpentier, B., Negrete, A. C., Frangos, J. A. & Intaglietta, M. Paradoxical hypotension following increased hematocrit and blood viscosity. Am. J. Physiol. Heart Circ. Physiol. 289, H2136–2143 (2005).
11. Tomaiuolo, G. Biomechanical properties of red blood cells in health and disease towards microfluidics. *Biomicrofluidics* **8**, 051501 (2014).

12. Wagenknecht, L. E. *et al.* Diabetes and progression of carotid atherosclerosis: the insulin resistance atherosclerosis study. *Arterioscler. Thromb. Vasc. Biol.* **23**, 1035–1041 (2003).

13. Guerci, B., Bohme, P., Kearney-Schwartz, A., Zannad, F. & Drouin, P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. *Diabetes Metab.* **27**, 436–447 (2001).

14. Massberg, S. *et al.* A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. *J. Exp. Med.* **196**, 887–896 (2002).

15. Yeom, E. & Lee, S. J. Microfluidic-based speckle analysis for sensitive measurement of erythrocyte aggregation: A comparison of four methods for detection of elevated erythrocyte aggregation in diabetic rat blood. *Biomicrofluidics* **9**, 024110 (2015).

16. Xue, W. L. *et al.* Effect of Trigonella foenum-graecum (fenugreek) extract on blood glucose, blood lipid and hemorheological properties in streptozotocin-induced diabetic rats. *Asia Pac. J. Clin. Nutr.* **16** Suppl 1, 422–426 (2007).

17. Yeom, E., Kang, Y. J. & Lee, S. J. Hybrid system for ex vivo hemorheological and hemodynamic analysis: A feasibility study. *Sci. Rep.* **5**, 11064 (2015).

18. Nam, K. H., Yeom, E. & Lee, S. J. Extracorporeal bypass model of blood circulation for the study of microvascular hemodynamics. *Microvasc. Res.* **83**, 372–375 (2012).

19. Shimomura, I. *et al.* Insulin selectively increases SREBP-1c mRNA in the livers of rats with streptozotocin-induced diabetes. *Proc. Natl. Acad. Sci. USA* **96**, 13656–13661 (1999).

20. Baskurt, O. K., Farley, R. A. & Meiselman, H. J. Erythrocyte aggregation tendency and cellular properties in horse, human, and rat: a comparative study. *Am. J. Physiol. Heart Circ. Physiol.* **273**, H2604–2612 (1997).

21. Cho, Y. I. & Kensey, K. R. Effects of the non-Newtonian viscosity of blood on flows in a diseased arterial vessel. Part 1: Steady flows. *Biomech. Model. Mechan. System.* **28**, 241–262 (1991).

22. Carreau, P. J., De Ke, D. & Chhabra, R. P. Rheology of polymeric systems: principles and applications. (Hanser Publishers Munich, 1997).

23. Van Oss, C. J., Arnold, K. & Coakley, W. T. Depletion flocculation and depletion stabilization of erythrocytes. *Cell Biophys.* **17**, 1–10 (1990).

24. Bishop, J. J., Popel, A. S., Intaglietta, M. & Johnson, P. C. Rheological effects of red blood cell aggregation in the venous network: a review of recent studies. *Biophysics* **38**, 263–274 (2001).

25. Reinhart, W. H. & Chien, S. Red cell rheology in stomatocyte-echinocyte transformation: roles of cell geometry and cell shape. *Blood* **67**, 1110–1118 (1986).

26. Park, Y. *et al.* Metabolic remodeling of the human red blood cell membrane. *Proc. Natl. Acad. Sci. USA* **107**, 1289–1294 (2010).

27. Haidara, M., Kloussy, H., Ammar, H. & Kassem, L. A. A. Impact of a-tocopherol and vitamin C on endothelial markers in rats with streptozotocin-induced diabetes. *Med. Sci. Monit.* **10**, Br41–Br46 (2004).

28. Caimi, G. *et al.* Diabetes mellitus: mean erythrocyte aggregation, glycometabolic pattern, red cell Ca2+ content, and erythrocyte membrane dynamic properties. *Microvasc. Res.* **46**, 401–405 (1993).

29. Singh, M. & Shin, S. Changes in erythrocyte aggregation and deformability in diabetes mellitus: a brief review. *Indian J. Exp. Biol.* **47**, 7–15 (2009).

30. Kesavan, S. K. *et al.* Proteome wide reduction in AGE modification in streptozotocin induced diabetic mice by hyaluridase mediated transglycosylation. *Sci. Rep.* **3**, 2941 (2013).

31. Li, Y. G. *et al.* 1-deoxynojirimycin inhibits glucose absorption and accelerates glucose metabolism in streptozotocin-induced diabetic mice. *Sci. Rep.* **3**, 1377 (2013).

32. Irace, C. *et al.* Influence of blood lipids on plasma and blood viscosity. *Clin. Hemorheol. Micron.** 57**, 267–274 (2014).

33. Khan, H. A. & Ola, M. S. Markers of blood coagulation, lipid profile, renal function test and serum electrolytes in streptozotocin-induced diabetic rats. *Biomed Res. India* **23**, 421–424 (2012).

34. Li, Q., Li, L. & Li, Y. Enhanced RBC aggregation in type 2 diabetes patients. *J. Clin. Lab. Anal.* **1**, 1–3 (2014).

35. Buys, A. V. *et al.* Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study. *Cardiovasc. Diabetol.* **12**, 25 (2013).

36. Mohamed, I., Wen, H. K., Idris, M. H., Zainalabidin, S. & Budin, S. B. Reduced red blood cell membrane damage in streptozotocin-induced diabetic rats supplemented with rosiglitazone (UKMR-2) calyx extract. *Pak. J. Biol. Sci.* **17**, 682–688 (2014).

37. Babu, N. & Singh, M. Influence of hyperglycaemia on aggregation, deformability and shape parameters of erythrocytes. *Clin. Hemorheol. Microcirc.* **31**, 273–280 (2004).

38. Sureka, G., Ramesh, T. & Begum, V. H. Attenuation of erythrocyte membrane oxidative stress by Sesbania grandiflora in streptozotocin-induced diabetic rats. *Biochem. Cell Biol.* **93**, 385–395 (2015).

39. Maxwell, M. J. *et al.* Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. *Blood* **109**, 566–576 (2007).

40. Nesbitt, W. S. *et al.* A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. *Nat. Med.* **16**, 665–673 (2009).

41. Ha, H. & Lee, S. J. Hemorheological dynamics features and platelet aggregation in a stenosed microchannel. *Microvasc. Res.* **90**, 96–105 (2013).

42. Savage, B., Saldivar, E. & Ruggeri, Z. M. Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. *Cell* **84**, 289–297 (1996).

43. Savage, B., Almus-Jacobs, F. & Ruggeri, Z. M. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. *Cell* **94**, 657–666 (1998).

44. Schwarz, U. R., Kobzar, A. L., Kocks, M., Walter, U. & Eigenthaler, M. Inhibition of agonist-induced p42 and p38 mitogen-activated protein kinase phosphorylation and CD40 ligand/P-selectin expression by cyclic nucleotide-regulated pathways in human platelets. *Biochem. Pharmacol.* **60**, 1399–1407 (2000).

45. Tovar-Lopez, F. J. *et al.* A microfluidics device to monitor platelet aggregation dynamics in response to strain rate micro-gradients in flowing blood. *Lab Chip* **10**, 291–302 (2010).

46. Yeom, E., Kang, Y. J. & Lee, S. J. Changes in velocity profile according to blood viscosity in a microchannel. *Biomicrofluidics* **8**, 034110 (2014).

47. Yeom, E., Nam, K. H., Paeng, D. G. & Lee, S. J. Improvement of ultrasound speckle image velocimetry using image enhancement techniques. *Ultrasonics* **54**, 205–216 (2014).

48. Kang, Y. J., Yeom, E. & Lee, S. J. A microfluidic device for simultaneous measurement of viscosity and flow rate of blood in a complex fluidic network. *Biomicrofluidics* **7**, 054111 (2013).

49. Canny, J. A computational approach to edge detection. *IEEE Trans. Pattern Anal. Mach. Intell.* **8**, 679–698 (1986).

50. Popescu, G., Ikeda, T., Dasari, R. R. & Feld, M. S. Diffraction phase microscopy for quantifying cell structure and dynamics. *Opt. Lett.* **31**, 775–777 (2006).

51. Seo, K. W., Choi, Y. S., Seo, E. S. & Lee, S. J. Aberration compensation for objective phase curvature in phase holographic microscopy. *Opt. Lett.* **37**, 4976–4978 (2012).

52. Yeom, E., Nam, K. H., Jin, C., Paeng, D. G. & Lee, S. J. 3D reconstruction of a carotid bifurcation from 2D transversal ultrasound images. *Ultrasonics* **54**, 2184–2192 (2014).
Acknowledgements
We greatly appreciate Dr. Nam’s permission to use the drawing of the rat in the schemes of the proposed system (Figures 1 and S2). This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea Government (MSIP) (No. 2008–0061991).

Author Contributions
E.Y. and S.J.L. proposed the study. E.Y. and H.B. performed the experiment and analyzed the data. E.Y. and S.J.L. wrote the paper. All authors participated in completing the manuscript.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Yeom, E. et al. Effect of diabetic duration on hemorheological properties and platelet aggregation in streptozotocin-induced diabetic rats. Sci. Rep. 6, 21913; doi: 10.1038/srep21913 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/